Tiny trial tests Dual-Radiation attack on returning prostate cancer
NCT ID NCT05230251
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tested whether adding a radioactive drug (177Lu-PSMA) to standard brachytherapy is safe and feasible for men whose prostate cancer returned after initial radiation. Only 3 men took part. The goal was to see if the combination could control cancer both in the prostate and elsewhere in the body. Because it was so small, the results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PNT2002 (a radioactive drug that targets prostate cancer cells)
What this could lead to
If it works, this combination could offer a new way to treat prostate cancer that has come back after initial radiation, potentially targeting cancer both inside and outside the prostate.
What could go wrong
This was a very small, early-phase study with only 3 participants, so results may not apply to most patients. The treatment also carries risks from radiation exposure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
London Health Sciences Centre
London, Ontario, N6A5W9, Canada